HF Advisory Group LLC Raises Position in GSK plc (NYSE:GSK)

HF Advisory Group LLC grew its stake in shares of GSK plc (NYSE:GSK) by 12.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,743 shares of the pharmaceutical company’s stock after purchasing an additional 990 shares during the quarter. HF Advisory Group LLC’s holdings in GSK were worth $296,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Eastern Bank bought a new position in GSK in the third quarter worth $26,000. Sunbelt Securities Inc. raised its stake in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 302 shares during the last quarter. Concord Wealth Partners boosted its holdings in GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 547 shares in the last quarter. ST Germain D J Co. Inc. grew its stake in shares of GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 522 shares during the last quarter. Finally, Fortitude Family Office LLC bought a new position in shares of GSK during the third quarter valued at $42,000. Institutional investors own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 13th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and dropped their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Price Performance

NYSE GSK opened at $33.46 on Friday. The stock has a market capitalization of $69.34 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The business’s fifty day moving average price is $34.02 and its 200-day moving average price is $37.98.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were issued a $0.3928 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a yield of 4.70%. GSK’s dividend payout ratio is currently 96.10%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.